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Introduction
Health equity and social determinants of health remain high on
international and national agendas. Recently, the report of the
World Conference on Social Determinants of Health (October
2011) recognized the need for increased availability of data on
inequities in health and resource allocation [1]. The Global
Symposium on Health Systems Research in 2010 also considered
equity to be of fundamental importance [2]. Despite such global
commitment, there continues to be a dearth of evidence on the
effects of policies on health equity [3].
Health equity is defined as the absence of avoidable and unfair
inequalities in health [4]. The moral judgment of fairness involves
an ethical debate about freedom, capabilities, and opportunities
with consideration of context [5]. Rigorous scientific measurement
and evaluation of the effects of policies on health equity is
necessary to meet the goals of the World Health Organization
Commission on Social Determinants of Health (WHO CSDH).
Studies of the average effects of interventions, which control for
confounding across individual and population-level characteristics,
hide their impact on health equity. Using average effects to guide
policy may even result in increases in health inequalities despite
good intentions, as shown by an assessment of the impacts of
country-level efforts in child health [6]. Well-designed, scientific
evaluations that assess effects on health equity are needed to break
the poverty trap [7].
Systematic reviews have, on one hand, been promoted as a
useful and comprehensive source of evidence for decision making
[8,9], and, on the other hand, have been criticized by decision
makers for not providing evidence about health equity [10,11].
Systematic reviews can address health equity questions in one of
three ways. First, they can assess effects of interventions targeted at
a disadvantaged population as done in a review on school feeding
for disadvantaged children [12]. Second, they can assess effects of
interventions aimed at reducing social gradients such as the review
on interventions to reduce the social gradient in smoking [10,13].
Third, they can assess effects of interventions not aimed at
reducing inequity but where it is important to understand the
effects of the intervention on equity, such as lay health workers
[14] or obesity prevention in children [15]. We estimate that
approximately 20% of systematic reviews indexed in MEDLINE
meet one or more of these criteria [16].
A focus on health equity in systematic reviews may uncover
evidence on intervention-generated inequalities [17], lack of
evidence and the need for further research [15], or greater
absolute impact for the poorest due to their poorer health status.
For example, vitamin A has the largest absolute impact on
mortality reduction for children with lowest nutritional status [18].
However, few systematic reviews assess effects on health equity
and those that do often provide insufficient detail to allow
replication, including poor reporting of some population charac-
teristics, subgroup analyses, and applicability judgments [19].
Reporting guidelines are designed to encourage completeness
and transparency in reporting methods and results of systematic
reviews, such as the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) Statement. Whilst there is
guidance on conducting equity-focused systematic reviews [20],
there is no guidance on reporting them. This is important because
several methodological issues are specific to reporting on
systematic reviews with a major focus on equity, such as how
disadvantaged populations are defined, how equity is incorporated
into syntheses, and how to report on the applicability of review
findings to disadvantaged populations or settings.
We therefore developed reporting guidelines for equity-focused
systematic reviews, and had two main goals: (1) to provide
structured guidance on transparently reporting these methods and
results, and (2) to legitimize and emphasize the importance of
reporting health equity results. We aim to contribute to improving
the evidence base for evidence-informed, equity-oriented policy
through wide dissemination of these reporting guidelines.
Methods
To produce these equity reporting guidelines (henceforth called
PRISMA-E 2012), we followed recommendations [21] for the
The Guidelines and Guidance section contains advice on conducting and
reporting medical research.
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development of health research reporting guidelines: the relevant
steps include identifying need, obtaining funding, reviewing the
literature, conducting a broad survey (Figure S1; Tables S2, S3,
S4, S5), and exploring consensus (see Figure 1).
Consensus Meeting
A two-day consensus meeting was held on February 9–10, 2012
at the Rockefeller Foundation Sfondrata conference centre in
Bellagio, Italy with 23 participants (Table S1). Its purpose was to
discuss and reach consensus on each proposed item to be included
in the PRISMA-E 2012 guidance. This guidance used the
PRISMA statement and guidance as a starting point. PRISMA
is an evidence-based minimum set of items for reporting in
systematic reviews and meta-analyses; it does not currently have
items relating explicitly to equity (www.prisma-statement.org) [22].
The meeting was organized to maximize participation and
minimize lengthy presentations. Each participant was assigned a
role to increase participation (Table S6). We provided all
participants with instructions about these roles prior to the meeting
(Table S7), and recorded all discussions and took detailed minutes.
We selected meeting participants on the basis of their expertise
in systematic reviews, geographic diversity (prioritizing represen-
tation of participants from low- and middle-income countries), and
representation of organizations that might use the reporting
guidelines.
The participants included journal editors (n=3), funders (n=2),
systematic review authors with a focus on low- and middle-income
countries (n=4), decision-making organizations (n=2), practition-
ers in public health or health care (n=5), and methodologists/
statisticians (n=4). Several participants represented more than one
of these groups, but are only counted once. There were seven
participants from low- and middle-income countries.
Results
The consensus meeting participants (hereafter referred to as
‘‘we’’) first agreed that the proposed equity reporting guidelines
should be developed as a stand-alone document, because there is
no set date for updating the PRISMA Statement and we felt that
health equity issues are of sufficient global importance that they
require explicit attention. Secondly, we agreed that the items were
intended to focus on description of what was done and how, as
with other reporting guidelines [21].
The proposed equity extension items are shown in Table 1,
column 2, with the original PRISMA items in the left column. The
rationale for these items is summarized below.
Title (1): Identify equity as a focus of the review, if
relevant, using the term equity. We agreed that it is very
important to facilitate identification of reviews that address equity.
We recognize this is not standard practice. In a search of all
systematic reviews in the last year, we found only seven with equity
in the title (Table S8). Thus, we propose that all equity-focused
reviews include equity in the title.
Structured Summary (2, 2A, 2B): State research
question(s) and present results related to health equity,
and assess applicability. We recognize that end-users may
only read the abstract. Therefore, it is critical that the abstract
details effects on equity.
Rationale (3 and 3A): Describe assumptions about
mechanism(s) by which the intervention is assumed to
have an impact on health equity, and provide analytic
framework (if done).We felt that equity-focused systematic reviews
need to define a priori how the intervention is expected to influence
health equity, so that these hypotheses can be tested. A visual
representation (analytic framework) can be very useful. For example,
they can show the causal chain [23]. Examples of using such
frameworks for systematic reviews are increasingly available [24,25].
Objectives (4 and 4A): Describe how disadvantage was
defined and research questions addressed. Health equity
and disadvantage are normative concepts, thus the systematic
review must define how these terms are operationalized. Research
questions related to equity need to be explicitly stated. For
example, socially disadvantaged mothers were defined as those
who were poor, lived in an inner-city environment, or were single
parents in one review [26].
Methods (6 and 6A): Provide rationale for eligible
study designs and outcomes. Equity questions may involve
interventions and/or outcomes that have not been assessed
through randomized evaluations. Therefore, we recommend
explicit consideration of eligible study designs based on fitness
for purpose [3,20] and that the rationale for these choices be
reported. Outcomes related to health equity need to be defined
since they may involve differences between more and less
advantaged groups. Furthermore, some questionnaire-based out-
comes need to be adapted for less advantaged people. For
example, a systematic review of culturally appropriate health
education assessed the influence of culturally adapted measure-
ment tools on knowledge outcomes using sensitivity analysis [27].
Information sources and search strategy (7 and 8):
Describe the relevance of databases and sources for
equity as well as any terms used related to equity
questions. We recommend searching broadly for equity-related
topics. Non-health databases such as transportation and econom-
ics may be relevant [28], as well as gray literature such as theses
and unpublished reports. It is important to note that equity limits
in the search could result in missing studies [29] unless these equity
search strategies are validated. For example, the Cochrane Child
Health filter [30] has been validated.
Data items (11): List and define data items related to
equity where such data were sought. We recommend using
an explicit checklist in the data extraction process to avoid missing
data on health equity. We recommend place of residence, race/
Summary Points
N There is a global imperative to tackle national and
international health inequities— defined as unfair and
avoidable differences in health.
N One step in reaching this goal is to improve the rigorous,
scientific evidence base on the impacts of policies on
inequities in health outcomes, resource allocation, and
use.
N Systematic reviews are increasingly recognized as a
valuable source of evidence for both health care and
health systems decision making, yet very few systematic
reviews report effects on health equity.
N We developed consensus-based reporting guidelines for
equity-focused systematic reviews in order to help
reviewers identify, extract, and synthesise evidence on
equity in systematic reviews.
N Increased use of these reporting guidelines will help
improve the reporting of effects on both inequities in
health outcomes and health care use across gender,
socioeconomic position, and other characteristics, both
in systematic reviews and eventually primary research,
thus contributing to the global agenda to improve
health equity.
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ethnicity/culture/language, occupation, gender/sex, religion, ed-
ucation, socioeconomic status, social capital and ‘‘plus’’ to indicate
other possible factors such as disease status or disability
(PROGRESS-Plus) [20]. Each of these characteristics requires
careful consideration regarding their definition and classification
as well as their interaction with other contextual elements and how
they influence health inequities. For example, there is no agreed
system for classifying race, ethnicity, and culture, particularly
across different countries [31]. The concept of ethnicity has a
relational dimension that helps in understanding social stratifica-
tion and social exposures, and this relational dimension depends
on context and setting [32]. The categorization of individuals
according to ethnic groups may have different results when
compared to individuals self-classification, and may also have
negative consequences [31]. For each element of PROGRESS-
Plus, authors need to consider whether health differences are
avoidable and thus considered health inequities. When possible,
systematic review authors should state how each element of
PROGRESS-Plus was conceptualized, how it is hypothesized to
affect health inequities, and how it was assessed. More limited
criteria may also be used. For example, in a review of school
feeding for disadvantaged children, data were sought on effects by
socioeconomic position, or proxies for socioeconomic position
such as nutritional status [12].
Synthesis of results (14): Describe methods of synthe-
sizing findings on health inequities. In our view, an equity-
focused review must present both relative and absolute differences
between groups. Policy makers are interested in the absolute
impact on deaths prevented or morbidity avoided. Furthermore,
the absolute impact is likely to be higher in disadvantaged groups
who are likely to have worse baseline health status. For example,
vitamin A for preventing morbidity and mortality in children from
6 months to 5 years of age found a 24% relative risk reduction,
which, in absolute terms, amounted to prevention of 22 deaths per
1,000 in a high-risk population but only three deaths per 1,000 in
a medium-risk population [18].
Additional analyses (16): Describe methods of addi-
tional synthesis approaches related to equity questions.
Additional quantitative or qualitative analyses may be necessary to
answer equity questions; these include causal pathway analysis and
process evaluation. For example, a review of school feeding
tabulated effects for each study according to effect modifiers such
as type of study, blinding versus unclear blinding, and high versus
low energy [12].
Results (18, 21, 23): Equity-focused reviews should
report all relevant population characteristics as well as
contextual factors that may be important for the
population and intervention of interest. We felt that the
Figure 1. Flowchart of methods used to develop PRISMA-E 2012 reporting guidelines for equity-focused systematic reviews. LMIC,
low- and middle-income country.
doi:10.1371/journal.pmed.1001333.g001
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Table 1. Checklist of items for reporting equity-focused systematic reviews.
Section Item Standard PRISMA Item Extension for Equity-Focused Reviews
Title
Title 1 Identify the report as a systematic review,
meta-analysis, or both.
Identify equity as a focus of the review, if relevant,
using the term equity.
Abstract
Structured summary 2 2. Provide a structured summary including, as
applicable: background; objectives; data sources;
study eligibility criteria, participants, and interventions;
study appraisal and synthesis methods; results;
limitations; conclusions and implications of key
findings; systematic review registration number.
State research question(s) related to health equity.
2A Present results of health equity analyses (e.g.,
subgroup analyses or meta-regression).
2B Describe extent and limits of applicability to
disadvantaged populations of interest.
Introduction
Rationale 3 Describe the rationale for the review in the context
of what is already known.
Describe assumptions about mechanism(s) by
which the intervention is assumed to have an
impact on health equity.
3A Provide the logic model/analytical framework,
if done, to show the pathways through which
the intervention is assumed to affect health equity
and how it was developed.
Objectives 4 Provide an explicit statement of questions being
addressed with reference to PICOS.
Describe how disadvantage was defined if used as
criterion in the review (e.g., for selecting studies,
conducting analyses, or judging applicability).
4A State the research questions being addressed with
reference to health equity
Methods
Protocol and
registration
5 Indicate if a review protocol exists, if and where it
can be accessed (e.g., web address), and, if
available, provide registration information
including registration number.
Eligibility criteria 6 6. Specify study characteristics (e.g., PICOS, length
of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as
criteria for eligibility, giving rationale.
Describe the rationale for including particular study
designs related to equity research questions.
6A Describe the rationale for including the outcomes
(e.g., how these are relevant to reducing inequity).
Information sources 7 Describe all information sources (e.g., databases
with dates of coverage, contact with study authors
to identify additional studies) in the search and
date last searched.
Describe information sources (e.g., health, non-health,
and grey literature sources) that were searched that
are of specific relevance to address the equity
questions of the review.
Search 8 Present full electronic search strategy for at least
one database, including any limits used, such that
it could be repeated.
Describe the broad search strategy and terms used
to address equity questions of the review.
Study selection 9 State the process for selecting studies (i.e.,
screening, eligibility, included in systematic
review, and, if applicable, included in the
meta-analysis).
Data collection
process
10 Describe method of data extraction from reports
(e.g., piloted forms, independently, in duplicate)
and any processes for obtaining and confirming
data from investigators.
Data items 11 List and define all variables for which data were
sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
List and define data items related to equity, where
such data were sought (e.g., using PROGRESS-Plus
or other criteria, context).
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias
of individual studies (including specification of
whether this was done at the study or outcome
level), and how this information is to be used in
any data synthesis.
Summary measures 13 State the principal summary measures (e.g.,
risk ratio, difference in means).
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reporting guideline should emphasize the need to present results of
all equity syntheses such as meta-regression and subgroup analyses
(item 21), even if lacking in data. We also propose an additional
item to describe the use of additional synthesis approaches such as
process evaluation or the use of qualitative data to answer equity
questions (item 23).
Conclusions (26, 26A): Present extent and limits of
applicability to disadvantaged populations of interest
Table 1. Cont.
Section Item Standard PRISMA Item Extension for Equity-Focused Reviews
Synthesis of results 14 Describe the methods of handling data and
combining results of studies, if done, including
measures of consistency (e.g., I2) for each
meta-analysis.
Describe methods of synthesizing findings on health
inequities (e.g., presenting both relative and absolute
differences between groups).
Risk of bias across
studies
15 15. Specify any assessment of risk of bias that
may affect the cumulative evidence (e.g., publication
bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses
(e.g., sensitivity or subgroup analyses,
meta-regression), if done, indicating which
were pre-specified.
Describe methods of additional synthesis approaches
related to equity questions, if done, indicating which
were pre-specified
Results
Study selection 17 Give numbers of studies screened, assessed for
eligibility, and included in the review, with
reasons for exclusions at each stage, ideally
with a flow diagram.
Study characteristics 18 For each study, present characteristics for which
data were extracted (e.g., study size, PICOS,
follow-up period) and provide the citations.
Present the population characteristics that relate to
the equity questions across the relevant PROGRESS-Plus
or other factors of interest.
Risk of bias within
studies
19 Present data on risk of bias of each study and,
if available, any outcome level assessment
(see item 12).
Results of individual
studies
20 For all outcomes considered (benefits or harms),
present, for each study: (a) simple summary data
for each intervention group; (b) effect estimates
and confidence intervals, ideally with a forest plot.
Synthesis of results 21 Present results of each meta-analysis done,
including confidence intervals and measures
of consistency.
Present the results of synthesizing findings on
inequities (see 14).
Risk of bias across
studies
22 Present results of any assessment of risk of bias
across studies (see item 15).
Additional analysis 23 Give results of additional analyses, if done
(e.g., sensitivity or subgroup analyses,
meta-regression [see item 16]).
Give the results of additional synthesis approaches
related to equity objectives, if done, (see 16).
Discussion
Summary of evidence 24 Summarize the main findings including the
strength of evidence for each main outcome;
consider their relevance to key groups
(e.g., health care providers, users, and policy
makers).
Limitations 25 Discuss limitations at study and outcome level
(e.g., risk of bias), and at review-level
(e.g., incomplete retrieval of identified research,
reporting bias).
Conclusions 26 Provide a general interpretation of the results
in the context of other evidence, and implications
for future research.
Present extent and limits of applicability to
disadvantaged populations of interest and describe
the evidence and logic underlying those judgments.
26A Provide implications for research, practice, or policy
related to equity where relevant (e.g., types of
research needed to address unanswered questions).
Funding
Funding 27 Describe sources of funding for the systematic
review and other support (e.g., supply of data);
role of funders for the systematic review.
This checklist should be read in conjunction with the Statement and Explanation and Elaboration document, when available.
PICOS, participants, interventions, comparisons, outcomes, and study design.
doi:10.1371/journal.pmed.1001333.t001
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and implications for research, practice, or policy
related to equity. We agreed that systematic reviewers cannot
make judgments about applicability or implications for practice
and policy for every possible setting. However, we feel that the
explicit reporting about applicability of findings to disadvantaged
populations of interest is necessary to increase their relevance to
decision makers (items 26 and 26A). For example, a Cochrane
review of lay health workers suggested considerations for the
assessment of applicability in different settings such as health
system characteristics and on the ground constraints [33].
Discussion
We have developed PRISMA-E 2012 to improve transparency
and completeness of reporting of systematic reviews with a major
focus on equity. We followed recent guidance on good practice in
guideline development [21]. This inclusive and evidence-based
process resulted in the proposal of 20 additional items to the
PRISMA Statement to improve reporting of equity-focused
systematic reviews.
Equity and fairness are of paramount importance to health care
decision making and resource allocation [34]. This equity
extension of PRISMA emphasizes the importance of enhancing
the reporting of methods and results relevant to health equity,
which we believe will improve the evidence base for equity-focused
decision making over time.
We have planned several post-publication activities to increase
dissemination and uptake of PRISMA-E 2012, such as presenta-
tions at conferences to reach decision makers, journal editors, and
researchers, as well as web-based strategies such as webinars, an
open-access website, and twitter. Readers can find out about post-
publication activities on the Campbell and Cochrane Equity
Methods Group website www.equity.cochrane.org.
To encourage journal endorsement, we will write to the nearly
200 PRISMA-endorsing journals and ask them to consider
endorsing PRISMA-E 2012, using affirmative, precise language
that has been shown to increase uptake, such as ‘‘[this journal]
requires a completed PRISMA-E 2012 checklist as a condition of
submission of systematic reviews whose main focus is equity. We
recommend you, while completing this form, consider amending
your manuscript to ensure your article addresses all issues raised
by the PRISMA-E 2012 checklist, where appropriate. Taking the
time to ensure your manuscript meets these basic reporting needs
will greatly improve your manuscript, potentially enhancing its
chances for eventual publication.’’ Similarly, we will contact
funding agencies and those commissioning systematic reviews to
consider recommending the use of PRISMA-E 2012. Grant peer
review committees can also use the reporting guideline. We will
evaluate the uptake of PRISMA-E 2012 by assessing the number
of journals that cite PRISMA-E 2012 in their instructions for
authors. We also plan to evaluate the influence of journal (and
potentially other organizations) endorsement of the PRISMA-E
2012 by comparing endorsing and non-endorsing journals
regarding reporting of PRISMA-E 2012 items in equity-focused
systematic reviews [35].
Our development process has a number of strengths including
the use of an inclusive process with input from intended users using
a web-based survey and consensus meeting. The main limitations
of our approach are that some terms are not widely accepted such
as ‘‘logic model’’ and ‘‘analytic framework.’’ There is no
universally accepted definition of ‘‘health equity.’’ We chose to
use Whitehead’s widely used definition as it differentiates simple
differences in outcomes from those that are inequitable due to
unfairness [4]. We acknowledge that our tool is limited to
improving the reporting of reviews already examining equity,
rather than improving equity research or indeed health equity
itself.
In conclusion, we hope that the use of this PRISMA-E 2012
guidance will improve both the reporting and conduct of equity-
focused reviews. In time, it may indirectly influence primary
research by identifying the need for new research studies to answer
health equity questions. Thus, we hope for this guidance to help
contribute to the goals of the Rio Political Declaration on Social
Determinants of Health [1] by improving the evidence base about
equity in health outcomes, access, and use of health care.
Supporting Information
Figure S1 Survey on SurveyMonkey.
(DOCX)
Table S1 PRISMA-Equity Bellagio Group.
(DOCX)
Table S2 Equity extension of PRISMA.
( )
Table S3 Distribution of online survey.
(DOCX)
Table S4 Characteristics of respondents of the survey
(n=423).
(DOCX)
Table S5 Responses to online survey.
(DOCX)
Table S6 Consensus meeting agenda.
(DOCX)
Table S7 Participant roles.
(DOCX)
Table S8 Systematic reviews with equity in the title (1-
08-2011 to 1-08-2012).
(DOCX)
Acknowledgments
The members of the PRISMA-Equity Bellagio group are:
Rifat Atun, Imperial College London, UK; Shally Awasthi, King George’s
Medical College, India; Virginia Barbour, PLOS Medicine, UK; Zulfiqar
Bhutta, Husein Laljee Dewraj Professor and Chairman, Department of
Paediatrics and Child Health, Aga Khan University Medical Center,
Pakistan; Luis Gabriel Cuervo, Research Promotion & Development, Pan
American Health Organization, USA; Jeremy Grimshaw, Ottawa Hospital
Research Institute, Canada; Trish Groves, Deputy Editor, BMJ, UK;
Tracey Koehlmoos-Perez, Health Systems and Infectious Disease Division,
International Centre for Diarrhoeal Disease Research (ICDDR,B),
Bangladesh; Elizabeth Kristjansson, School of Psychology, Faculty of
Social Sciences, University of Ottawa, Canada; David Moher, Ottawa
Hospital Research Institute, Canada; Jennifer O’Neill, Campbell and
Cochrane Equity Methods Group, Centre for Global Health, University of
Ottawa, Canada; Andy Oxman, Global Health Unit, Norwegian
Knowledge Centre for Health Services, Cochrane EPOC Review Group,
WHO Advisory Committee on Health Research, Norway; Tomas Pantoja,
Universidad Cato´lica de Chile, Santiago, Systematic Review Methods
Centre Cochrane EPOC editor, Alliance for Health Systems and Policy
Research, Chile; Mark Petticrew, London School of Hygiene and Tropical
Medicine, Campbell and Cochrane Equity methods group, UK; Terri
Pigott, Campbell Methods Coordinating Group; Campbell Statistics
Group, Loyola University Chicago, USA; Kent Ranson, Alliance for
Health Systems and Policy Research, WHO, Switzerland; Tessa
TanTorres, World Health Organization, Choosing Interventions that are
Cos-Effective (WHO-CHOICE), Switzerland; Prathap Tharyan, Co-
chrane Evidence Aid, Department of Psychiatry; Cochrane Schizophrenia
PLOS Medicine | www.plosmedicine.org 6 October 2012 | Volume 9 | Issue 10 | e1001333
PDF
Group; Coordinator, South Asian Cochrane Network - India, India; David
Tovey, The Cochrane Library, UK; Peter Tugwell, University of Ottawa,
Cochrane Musculoskeletal Review Group, Campbell and Cochrane Equity
methods group, Canada; Jimmy Volmink, Cochrane HIV/AIDS Review
Group; South Africa Cochrane Centre, Medical Research Council of
South Africa; Stellenbosch University, South Africa; Liz Wager, Sideview,
UK; Elizabeth Waters, Melbourne School of Population Health, The
University of Melbourne, Australia; Vivian Welch, Ottawa Hospital
Research Institute, Campbell and Cochrane Equity Methods Group,
Institute of Population Health, Centre for Global Health, University of
Ottawa, Canada; George Wells, Cardiovascular Research Methods Cen-
tre, University of Ottawa Heart Institute,  
ized Studies Methods Group; Howard White, International Initiative for
Impact Evaluation (3ie); Campbell International Development Coordi-
nating Group, India.
Author Contributions
Analyzed the data: VW MP PT DM JO EW HW. Wrote the first draft of
the manuscript: VW. Contributed to the writing of the manuscript: VW
MP PT DM JO EW HW. ICMJE criteria for authorship read and met:
VW MP PT DM JO EW HW. Agree with manuscript results and
conclusions: VW MP PT DM JO EW HW.
References
1. World Health Organization (2011) Rio Political Declaration on Social
Determinants of Health. World Conference on Social Determinants of Health.
Rio de Janeiro, Brazil. 19–21 October 2011. Available: http://www.who.int/
sdhconference/en/. Accessed 26 September 2012.
2. Bosch-Capblanch X, Lavis JN, Lewin S, Atun R, Rottingen JA, et al. (2012)
Guidance for evidence-informed policies about health systems: rationale for and
challenges of guidance development. PLoS Med 9: e1001185. doi:10.1371/
journal.pmed.1001185.
3. Ostlin P, Schrecker T, Sadana R, Bonnefoy J, Gilson L, et al. (2011) Priorities
for research on equity and health: towards an equity-focused health research
agenda. PLoS Med 8: e1001115. doi:10.1371/journal.pmed.1001115.
4. Whitehead M (1992) The concepts and principles of equity and health.
Int J Health Serv 22: 429–445.
5. Sen A (2002) Why health equity? Health Econ 11: 659–666.
6. Moser KA, Leon DA, Gwatkin DR (2005) How does progress towards the child
mortality millennium development goal affect inequalities between the poorest
and least poor? Analysis of Demographic and Health Survey data. BMJ 331:
1180–1182.
7. Banerjee A, Duflo E (2011) Poor economics: a radical rethinking of the way to
fight global poverty. New York: PublicAffairs. 320 p.
8. Lavis JN, Rottingen JA, Bosch-Capblanch X, Atun R, El-Jardali F, et al. (2012)
Guidance for evidence-informed policies about health systems: linking guidance
development to policy development. PLoS Med 9: e1001186. doi:10.1371/
journal.pmed.1001186.
9. Panisset U, Koehlmoos TP, Alkhatib AH, Pantoja T, Singh P, et al. (2012)
Implementation research evidence uptake and use for policy-making. Health
Res Policy Syst 10: 20.
10. Petticrew M, Whitehead M, Macintye SJ, Graham H, Egan M (2004) Evidence
for public health policy on inequalities: 1: the reality according to policymakers.
J Epidemiol Community Health 58: 811–816.
11. Lavis JN, Davies HTO, Gruen RL (2006) Working within and beyond the
Cochrane Collaboration to make systematic reviews more useful to healthcare
managers and policy makers. Healthcare Policy 1: 21–33.
12. Kristjansson EA, Robinson V, Petticrew M, MacDonald B, Krasevec J, et al.
(2007) School feeding for improving the physical and psychosocial health of
disadvantaged elementary school children. Cochrane Database Syst Rev 1:
CD004676.
13. Thomson G, Hudson S, Wilson N, Edwards R (2010) A qualitative case study of
policy maker views about the proctection of children from smoking in cars.
Nicotine Tob Res 12: 970–977.
14. Oxman AD, Lavis JN, Lewin S, Fretheim A (2009) SUPPORT Tools for
evidence-informed health Policymaking (STP) 10: taking equity into consider-
ation when assessing the findings of a systematic review. Health Res Policy Syst
7: S10.
15. Waters E, de Silva-Sanigorski A, Hall BJ, Brown T, Campbell KJ, et al. (2011)
Interventions for preventing obesity in children. Cochrane Database Syst Rev
12: CD001871.
16. Welch V, Smylie JK, Kristjansson E, Brand K, Tugwell P, et al. (2010) What is
the role of systematic reviews in tackling health inequity? Ottawa: University of
Ottawa.
17. Lorenc T, Petticrew M, Welch V, P T (2012) What types of interventions
generate inequalities? Evidence from systematic reviews. J Epidemiol Commu-
nity Health. In press.
18. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA (2010) Vitamin A
supplementation for preventing morbidity and mortality in children from 6
months to 5 years of age. Cochrane Database Syst Rev 12: CD008524.
19. Welch V, Tugwell P, Petticrew M, de Montigny J, Ueffing E, et al. (2010) How
effects on health equity are assessed in systematic reviews of interventions.
Cochrane Database Syst Rev 3: MR000028.
20. Tugwell P, Petticrew M, Kristjansson E, Welch V, Ueffing E, et al. (2010)
Assessing equity in systematic reviews: realising the recommendations of the
Commission on Social Determinants of Health. BMJ 341: c4739.
21. Moher D, Schulz KF, Simera I, Altman DG (2010) Guidance for developers of
health research reporting guidelines. PLoS Med 7: e1000217. doi:10.1371/
journal.pmed.1000217
22. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:
e1000097. doi:10.1371/journal.pmed.1000097
23. White H (2009) Theory-based impact evaluation: principles and practice.
Internatinoal initiative for impact evaluation. Available: http://www.3ieimpact.
org/en/evaluation/working-papers/working-paper-3/. Accessed 26 September
2012.
24. Anderson LM, Petticrew M, Rehfuess E, Armstrong R, Ueffing E, et al. (2011)
Using Logic models to capture complexity in systematic reviews. Res Synth
Method 2: 33–42.
25. Niederdeppe J, Lliang X, Crock B, Skelton A (2008) Media campaigns to
promote smoking cessation among socioeconomically disadvantaged popula-
tions: what do we know, what do we need to learn, and what should we do now?
Soc Sci Med 67: 1343–1355.
26. Macdonald G, Bennett C, Higgins JPT, Dennis JA (2010) Home visiting for
socially disadvantaged mothers (Protocol). Cochrane Database Syst Rev 10:
CD008784.
27. Hawthorne K, Robles Y, Cannings-John R, Edwards AG (2008) Culturally
appropriate health education for type 2 diabetes mellitus in ethnic minority
groups. Cochrane Database Syst Rev 3: CD006424.
28. Ogilvie D, Hamilton V, Egan M, Petticrew M (2005) Systematic reviews of
health effects of social interventions: 1. Finding the evidence: how far should you
go? J Epidemiol Community Health 59: 804–808.
29. Pienaar E, Grobler L, Busgeeth K, Eisinga A, Siegfried N (2011) Developing a
geographic search filter to identify randomised controlled trials in Africa: finding
the optimal balance between sensitivity and precision. Health Info Libr J 28:
210–215.
30. Leclercq E, Leeflang M-MG, van-Dalen E-C (2010) [P121] Validation of a
PubMed search filter for identifying studies including children. Cochrane
Colloquium Abstracts Journal. 18th Cochrane Colloquium and the 10th
Campbell Colloquium, Keystone, Colorado, 18–22 October 2010. Available:
http://www.imbi.uni-freiburg.de/OJS/cca/index.php?journal= cca&page=article
&op=view&path%5B%5D=9626. Accessed 26 September 2012.
31. Aspinall PJ (2007) Approaches to developing an improved cross-national
understanding of concepts and terms relating to ethnicity and race. Int Sociol 22:
41–70.
32. Ford CL, Harawa NT (2010) A new conceptualization of ethnicity for social
epidemiologic and health equity research. Soc Sci Med 71: 251–258.
33. Lewin S, Munabi-Babigumira S, Glenton C, Daniels K, Bosch-Capblanch X, et
al. (2010) Lay health workers in primary and community health care for
maternal and child health and the management of infectious diseases. Cochrane
Database Syst Rev 3: CD004015.
34. Guindo LA, Wagner M, Baltussen R, Rindress D, van Til J, et al. (2012) From
efficacy to equity: literature review of decision criteria for resource allocation and
healthcare decisionmaking. Cost Eff Resour Alloc 10: 9.
35. Turner L, Moher D, Shamseer L, Weeks L, Peters J, et al. (2011) The influence
of CONSORT on the quality of reporting of randomised controlled trials: an
updated review. Trials 12: A47.
PLOS Medicine | www.plosmedicine.org 7 October 2012 | Volume 9 | Issue 10 | e1001333
Non-Random-Cochrane
